All
Kisqali Plus Endocrine Therapy Improves Survival in HR+/HER2– Breast Cancer
December 6th 2023Patients with HR-positive HER2-negative advanced breast cancer, including elderly patients, derived a progression-free and overall survival benefit with Kisqali plus endocrine therapy compared with placebo plus endocrine therapy.
Augtyro ‘Fills a Gap’ in the Treatment of ROS1-Positive NSCLC
December 4th 2023The recent FDA approval of the next-generation tyrosine kinase inhibitor Augtyro provides patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer another treatment option when the disease becomes resistant to other therapies.